

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Karl-Heinz ALTMAN et al.
U.S. APPLICATION NO: 10/591,921
35 USC §371 DATE: 30 May 2007
FOR: Epothilone Derivatives

PETITION REGARDING PATENT TERM ADJUSTMENT
UNDER 37 C.F.R. §1.705(d)

Sir:

In accordance with Applicants duty of candor and good faith of the U.S. Patent and Trademark Office (hereinafter, the "Office"), Applicants note that a reply in regards to the Determination of Patent Term Adjustment transmitted 29 June 2010 with the Notice of Allowance is submitted via EFS-Web.

Applicants believe the PTA should be reduced by 646 days.

Conclusion

It is hereby requested that the Patent Office verify the calculation of the Patent Term Adjustment for the present application.

Patentee requests a waiver of any additional fees required for filing this petition, however, the Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-4409.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139

(617) 871-5098
Date: 3 January 2011

/Arlene K. Musser/
Arlene K. Musser
Attorney for Applicant
Reg. No. 37,895